Cardiometabolic risk reductions in patients with type 2 diabetes mellitus newly treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world administrative database study in Japan.
Atsunori KashiwagiShingo ShojiYoshinori KosakaiTadashi KogaKeiko AsakawaMitsuhiro RokudaPublished in: Journal of diabetes investigation (2022)
In the present study, SGLT2i showed favorable cardiometabolic risk reduction and longer treatment persistence than DPP4i in Japanese patients with type 2 diabetes mellitus.
Keyphrases